FibroGen Inc. Executive Compensation Details Revealed
Ticker: KYNB · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, sec-filing, DEF 14A
TL;DR
FibroGen's 2025 DEF 14A shows exec comp details, including equity award changes and dividends.
AI Summary
FibroGen Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on changes in the fair value of equity awards granted in prior years and dividends or other earnings paid on equity awards not otherwise reflected in total compensation for the covered year.
Why It Matters
This filing provides transparency into how FibroGen Inc. compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing providing standard executive compensation disclosures.
Key Players & Entities
- FibroGen Inc. (company) — Filer of the DEF 14A
- 20250425 (date) — Filing date
- December 31, 2024 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of FibroGen Inc.'s executive officers and directors for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What specific compensation elements are highlighted in the filing related to prior year equity awards?
The filing highlights changes in the fair value of outstanding and unvested equity awards granted in prior years, as well as dividends or other earnings paid on equity awards not otherwise reflected in total compensation for the covered year.
What is the fiscal year end for which this compensation information is being reported?
The compensation information is being reported for the fiscal year ending December 31, 2024.
What is FibroGen Inc.'s Standard Industrial Classification (SIC) code?
FibroGen Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding FIBROGEN INC (KYNB).